KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2017 - 2024)

Teva Pharmaceutical Industries' Asset Writedowns and Impairment history spans 8 years, with the latest figure at $679.0 million for Q1 2024.

  • For the quarter ending Q1 2024, Asset Writedowns and Impairment rose 259.26% year-over-year to $679.0 million, compared with a TTM value of $1.6 billion through Mar 2024, down 36.53%, and an annual FY2023 reading of $1.1 billion, down 55.95% over the prior year.
  • Asset Writedowns and Impairment for Q1 2024 was $679.0 million at Teva Pharmaceutical Industries, up from $68.0 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $5.2 billion in Q3 2020, with the low at $28.0 million in Q3 2022.
  • Average Asset Writedowns and Impairment over 5 years is $666.8 million, with a median of $227.0 million recorded in 2021.
  • Year-over-year, Asset Writedowns and Impairment surged 2433.66% in 2020 and then crashed 99.1% in 2021.
  • Tracing TEVA's Asset Writedowns and Impairment over 5 years: stood at $232.0 million in 2020, then dropped by 21.12% to $183.0 million in 2021, then skyrocketed by 689.62% to $1.4 billion in 2022, then crashed by 95.29% to $68.0 million in 2023, then surged by 898.53% to $679.0 million in 2024.
  • Per Business Quant, the three most recent readings for TEVA's Asset Writedowns and Impairment are $679.0 million (Q1 2024), $68.0 million (Q4 2023), and $48.0 million (Q3 2023).